SEARCH

SEARCH BY CITATION

References

  • 1
    Nehra A, Goldstein I, Pabby A, Nugent M, Huang YH, De Las Morenas A, Krane RJ, Udelson D, Saenz de Tejada I, Moreland RB. Mechanisms of venous leakage: A prospective clinicopathological correlation of corporeal function and structure. J Urol 1996;156: 13209.
  • 2
    Nehra A, Azadzoi KM, Moreland RB, Pabby A, Siroky MB, Krane RJ, Goldstein I, Udelson D. Cavernosal expandability is an erectile tissue mechanical property which predicts trabecular histology in an animal model of vasculogenic erectile dysfunction. J Urol 1998;159: 222936.
  • 3
    Yaman O, Yilmaz E, Bozlu M, Anafarta K. Alterations of intracorporeal structures in patients with erectile dysfunction. Urol Int 2003;71: 8790.
  • 4
    Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999;140: 18618.
  • 5
    Rogers RS, Graziottin TM, Lin CM, Kan YW, Lue T. Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats. Int J Impot Res 2003;15: 2637.
  • 6
    Robel P, Schumacher M, Baulieu E-E. Neurosteroids from definition and biochemistry to physiologic function. In: BaulieuEE, RobelP, SchumacherM, eds. Neurosteroids. Totowa, New Jersey: Human Press; 1999: 126.
  • 7
    Auchus RJ. The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab 2004;15: 4328.
  • 8
    Foresta C, Coretta N, Rosatto M, Garolla A, Ferlin A. Role of androgens in erectile function. J Urol 2004;171: 235862.
  • 9
    Gray PB, Singh AB, Woodhouse LJ, Storer TW, Casaburi R, Dzekov J, Dzekov C, Sinha-Hikim I, Bhasin S. Dose-dependent effects of testosterone on sexual function, mood and visuospatial cognition in older men. J Clin Endocrinol Metab 2005;90: 383846.
  • 10
    Dorfman RI, Shipley RA. Androgens: Biochemistry, physiology, and clinical significance. New York: John Wiley & Sons Inc.; 1956.
  • 11
    Harle L, Basaria S, Dobs AS. Nebido: A long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin Pharmacother 2005;6: 17519.
  • 12
    Jockenhovel F. Testosterone therapy—What, when and to whom? Aging Male 2004;7: 31924.
  • 13
    Giuliano F, Tostain J, Rossi D. Testosterone and male sexuality: Basic research and clinical data. Prog Urol 2004;14: 78390.
  • 14
    Amar E, Grivel T, Hamidi K, Lemaire A, Giuliano F. Ageing men's sexual functions decline and the erectile dysfunction (ED) increase. Prog Urol 2005;15: 69.
  • 15
    Rhoden EL, Teloken C, Mafessoni R, Souto CA. Is there any relation between serum levels of total testosterone and the severity of erectile dysfunction? Int J Impot Res 2002;14: 16771.
  • 16
    Rhoden EL, Teloken C, Sogari PR, Souto CA. The relationship of serum testosterone to erectile function in normal aging men. J Urol 2002;167: 17458.
  • 17
    Morales A, Buvat J, Gooren LJ, Guay AT, Kaufman J, Tan HM, Torres LO. Endocrine aspects of sexual dysfunction in men. J Sex Med 2004;1: 6981.
  • 18
    Rhoden EL, Morgentaler A. Treatment of testosterone-induced gynecomastia with the aromatase inhibitor, anastrozole. Int J Impot Res 2004;16: 957.
  • 19
    Rhoden EL, Morgentaler A. Risks of testosterone replacement—Replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 48292.
  • 20
    Bancroft J. The endocrinology of sexual arousal. J Endocrinol 2005;186: 41127.
  • 21
    Lazarou S, Morgentaler A. Hypogonadism in the man with erectile dysfunction: What to look for and when to treat. Curr Urol Rep 2005;6: 47681.
  • 22
    Baba K, Yajima M, Carrier S, Akkus E, Reman J, Nunes L, Lue TF, Iwamoto T. Effect of testosterone on the number of NADPH diaphorase-stained nerve fibers in the rat corpus cavernosum and dorsal nerve. Urology 2000;56: 5338.
  • 23
    Baba K, Yajima M, Carrier S, Morgan DM, Nunes L, Lue TF, Iwamoto T. Delayed testosterone replacement restores nitric oxide synthase-containing nerve fibres and the erectile response in rat penis. BJU Int 2000;85: 9538.
  • 24
    Bivalacqua TJ, Rajasekaran M, Champion HC, Wang R, Sikka SC, Kadowitz PJ, Hellstrom WG. The influence of castration on pharmacologically induced penile erection in the cat. J Androl 1998;19: 5517.
  • 25
    Lugg JA, Rajfer J, Gonzalez-Cadavid NF. Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology 1995;136: 1495501.
  • 26
    Mills TM, Lewis RW. The role of androgens in the erectile response: A perspective. Mol Urol 1999;3: 7586.
  • 27
    Mills TM, Lewis RW, Stopper VS. Androgenic maintenance of inflow and veno-occlusion during erection in the rat. Biol Reprod 1998;59: 14138.
  • 28
    Mills TM, Stopper VS, Reilly CM. Sites of androgenic regulation of cavernosal blood pressure during penile erection in the rat. Int J Impot Res 1996;8: 2934.
  • 29
    Mills  TM, Stopper VS, Wiedmeier VT. Effects of castration and androgen replacement on the hemodynamics of penile erection in the rat. Biol Reprod 1994;51: 2348.
  • 30
    Mills TM, Wiedmeier VT, Stopper VS. Androgen maintenance of erectile function in the rat penis. Biol Reprod 1992;46: 3428.
  • 31
    Muller SC, Hsieh JT, Lue TF, Tanagho EA. Castration and erection: An animal study. Eur Urol 1988;15: 11824.
  • 32
    Park KH, Kim SW, Kim KD, Paick JS. Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum. BJU Int 1999;83: 32733.
  • 33
    Reilly CM, Stopper VS, Mills TM. Androgens modulate the alpha-adrenergic responsiveness of vascular smooth muscle in the corpus cavernosum. J Androl 1997;18: 2631.
  • 34
    Reilly CM, Zamorano P, Stopper VS, Mills TM. Androgenic regulation of NO availability in rat penile erection. J Androl 1997;18: 1105.
  • 35
    Reilly CM, Lewis RW, Stopper VS, Mills TM. Androgenic maintenance of the rat erectile response via a non-nitric-oxide-dependent pathway. J Androl 1997;18: 58894.
  • 36
    Traish AM, Munarriz R, O'Connell L, Choi S, Kim SW, Kim NN, Huang YH, Goldstein I. Effects of medical or surgical castration on erectile function in an animal model. J Androl 2003;24: 3817.
  • 37
    Traish AM, Toselli P, Jeong SJ, Kimm NN. Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: A potential mechanism for venoocclusive dysfunction in androgen deficiency. J Androl 2005;26: 2428.
  • 38
    Zhang X, Morelli A, Luconi M, Vignozzi L, Marini M, Vannelli GB, Mancina R, Forti G, Maggi M. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur Urol 2005;47: 40916.
  • 39
    Zvara P, Sioufi R, Schipper HM, Begin LR, Brock GB. Nitric oxide mediated erectile activity is a testosterone dependent event: A rat erection model. Int J Impot Res 1995;7: 20919.
  • 40
    Aversa A, Isidori AM, De Martino MU, Caprio M, Fabbrini E, Rocchietti-March M, Frajese G, Fabbri A. Androgens and penile erection: Evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol (Oxf ) 2000;53: 51722.
  • 41
    Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilatation and response to sildenafil in patients with erectile dysfunction. Clin Endo 2003;58: 6328.
  • 42
    Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004;172: 65863.
  • 43
    Seftel AD, Mack RJ, Secrest AR, Smith TM. Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. J Androl 2004;25: 96372.
  • 44
    Morales A, Lunenfeld B. Androgen replacement therapy in the aging male with secondary hypogonadism. Aging Male 2001;4: 15162.
  • 45
    Cunningham GR, Hirshkowitz M. Inhibition of steroid 5 alpha-reductase with finasteride: Sleep-related erections, potency, and libido in healthy men. J Clin Endocrinol Metab 1995;80: 193440.
  • 46
    Tosti A, Pazzaglia M, Soli M, Rossi A, Rebora A, Atzori L, Barbareschi M, Benci M, Voudouris S, Vena GA. Evaluation of sexual function with an international index of erectile function in subjects taking finasteride for androgenetic alopecia. Arch Dermatol 2004;140: 8578.
  • 47
    Uygur MC, Arik AI, Altug U, Erol D. Effects of the 5 alpha-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: A prospective clinical study. Steroids 1998;63: 20813.
  • 48
    Uygur MC, Gur E, Arik AI, Altug U, Erol D. Erectile dysfunction following treatments of benign prostatic hyperplasia: A prospective study. Andrologia 1998b;30: 510.
  • 49
    Anderson RA, Martin CW, Kung AW, Everington D, Pun TC, Tan KC, Bancroft J, Sundaram K, Moo-Young AJ, Baird DT. 7Alpha-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men. J Clin Endocrinol Metab 1999;84: 355662.
  • 50
    Anderson RA, Wallace AM, Sattar N, Kumar N, Sundaram K. Evidence for tissue selectivity of the synthetic androgen 7a-methyl-19-nortestosterone in hypogonadal men. J Clin Endocrinol Metab 2003;88: 278493.
  • 51
    Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G, ARIA3001, ARIA3002, and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60: 43441.
  • 52
    Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M, Morrill B, Wolford ET. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004;63: 70915.
  • 53
    Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 2005;47: 82437.
  • 54
    Bradshaw WG, Baum MJ, Awh CC. Attenuation by a 5 alpha-reductase inhibitor of the activational effect of testosterone propionate on penile erections in castrated male rats. Endocrinology 1981;109: 104751.
  • 55
    Allen TD. Microphallus: Clinical and endocrinological characteristics. J Urol 1978a;119: 7503.
  • 56
    Allen TD. Microphallus: Clinical and endocrinological characteristics. Trans Am Assoc Genitourin Surg 1978b;70: 3841.
  • 57
    Ben-Galim E, Hillman RE, Weldon VV. Topically applied testosterone and phallic growth: Its effects in male children with hypopituitarism and microphallus. Am J Dis Child 1980;134: 2968.
  • 58
    Choi SK, Han SW, Kim DH, De Lignieres B. Transdermal dihydrotestosterone therapy and its effects on patients with microphallus. J Urol 1993;150: 65760.
  • 59
    Ogata T, Muroya K, Ishii T, Suzuki Y, Nakada T, Sasagawa I. Undermasculinized genitalia in a boy with an abnormally expanded CAG repeat length in the androgen receptor gene. Clin Endocrinol (Oxf ) 2001;54: 8358.
  • 60
    Gad YZ, Nasr H, Mazen I, Salah N, El-Ridi R. 5 alpha-reductase deficiency in patients with micropenis. J Inherit Metab Dis 1997;20: 95101.
  • 61
    Arisaka O, Hoshi M, Kanazawa S, Nakajima D, Numata M, Nishikura K, Oyama M, Nitta A, Kuribayashi T, Kano K, Nakayama Y, Yamashiro Y. Systemic effects of transdermal testosterone for the treatment of microphallus in children. Pediatr Int 2001;43: 1346.
  • 62
    Tsur H, Shafir R, Shachar J, Eshkol A. Microphallic hypospadias: Testosterone therapy prior to surgical repair. Br J Plast Surg 1983;36: 398400.
  • 63
    Kaufman FR, Costin G, Goebelsmann U, Stanczyk FZ, Zachmann M. Male pseudohermaphroditism due to 17,20-desmolase deficiency. J Clin Endocrinol Metab 1983;57: 326.
  • 64
    Grino PB, Isidro-Gutierrez RF, Griffin JE, Wilson JD. Androgen resistance associated with a qualitative abnormality of the androgen receptor and responsive to high dose androgen therapy. J Clin Endocrinol Metab 1989;68: 57884.
  • 65
    Walsh PC, Wilson JD, Allen TD, Madden JD, Porter JC, Neaves WB, Griffin JE, Goodwin WE. Clinical and endocrinological evaluation of patients with congenital microphallus. J Urol 1978;120: 905.
  • 66
    Ellis WJ, Grayhack JT. Sexual function in aging males after orchiectomy and estrogen therapy. J Urol 1963;89: 8958.
  • 67
    Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 1987;317: 599604.
  • 68
    Rousseau L, Dupont A, Labrie F, Couture M. Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen flutamide with medical (LHRH agonist) or surgical castration. Arch Sex Behav 1988;17: 8798.
  • 69
    Marumo K, Baba S, Murai M. Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone-releasing hormone agonist therapy. Int J Urol 1999;6: 1923.
  • 70
    Greenstein A, Plymate SR, Katz PG. Visually stimulated erection in castrated men. J Urol 1995;153: 6502.
  • 71
    Hirshkowitz M, Moore CA, O'Connor S, Bellamy M, Cunningham GR. Androgen and sleep-related erections. J Psychosom Res 1997;42: 5416.
  • 72
    Eri LM, Tveter KJ. Safety, side effects and patient acceptance of the luteinizing hormone releasing hormone agonist leuprolide in treatment of benign prostatic hyperplasia. J Urol 1994;152: 44852.
  • 73
    Eri LM, Tveter KJ. Safety, side effects and patient acceptance of the antiandrogen Casodex in the treatment of benign prostatic hyperplasia. Eur Urol 1994;26: 21926.
  • 74
    Handelsman DJ, Zajac JD. Androgen deficiency and replacement therapy in men. Med J Aust 2004;180: 52935.
  • 75
    Mulhall JP, Valenzuela R, Aviv N, Parker M. Effect of testosterone supplementation on sexual function in hypogonadal men with erectile dysfunction. Urology 2004;63: 34853.
  • 76
    Christ-Crain M, Mueller B, Gasswer TC, Kraenzlin M, Trummler M, Huber P, Meier C. Is there a clinical relevance of partial androgen deficiency of the aging male? J Urol 2004;172: 6247.
  • 77
    Bettocchi C, Palumbo F, Cormio L, Ditonno P, Battaglia M, Selvaggi FP. The effects of androgen depletion on human erectile function: A prospective study in male-to-female transsexuals. Int J Impot Res 2004;16: 5446.
  • 78
    Kratzik CW, Schatzl G, Lunglmayr G, Rucklinger E, Huber J. The impact of age, body mass index and testosterone on erectile dysfunction. J Urol 2005;174: 2403.
  • 79
    Ojumu A, Dobs AS. Is hypogonadism a risk factor for sexual dysfunction. J Androl 2003;24: S4651.
  • 80
    Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 2004;89: 38137.
  • 81
    Haren MT, Wittert GA, Chapman IM, Coates P, Morley JE. Effect of oral testosterone undecanoate on visuospatial cognition, mood and quality of life in elderly men with low-normal gonadal status. Maturitas 2005;50: 12433.
  • 82
    Haren MT, Chapman IM, Coates P, Morley JE, Wittert GA. Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low normal gonadal status. Age Ageing 2005;34: 12530.
  • 83
    Svartberg J, Aasebo U, Hjalmarsen A, Sundsfjord J, Jorde R. Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial. Respir Med 2004;98: 90613.
  • 84
    Svartberg J. Should older men be treated with testosterone? Tidsskr Nor Laegeforen 2005;125: 87982.
  • 85
    Albrecht-Betancourt M, Hijazi RA, Cunningham GR. Androgen replacement in men with hypogonadism and erectile dysfunction. Endocrine 2004;23: 1438.
  • 86
    Corona G, Mannucci E, Mansani R, Petrone L, Bartolini M, Giommi R, Mancini M, Forti G, Maggi M. Aging and pathogenesis of erectile dysfunction. Int J Impot Res 2004;16: 395402.
  • 87
    Murray FT, Wyss HU, Thomas RG, Spevack M, Glaros AG. Gonadal dysfunction in diabetic men with organic impotence. J Clin Endocrinol Metab 1987;65: 12735.
  • 88
    Kumamoto Y, Yamaguchi Y, Sato Y, Suzuki R, Tanda H, Kato S, Mori K, Matsumoto H, Maki A, Kadono M. Effects of anti-androgens on sexual function. Double-blind comparative studies on allylestrenol and chlormadinone acetate. Part I: Nocturnal penile tumescence monitoring. Hinyokika Kiyo 1990;36: 21326.
  • 89
    Schiavi RC, White D, Mandeli J, Schreiner-Engel P. Hormones and nocturnal penile tumescence in healthy aging men. Arch Sex Behav 1993;22: 20715.
  • 90
    Horita H, Kumamoto Y. Study on nocturnal penile tumescence (NPT) in healthy males: Study on the relationship between the serum free testosterone level and NPT. Nippon Hinyokika Gakkai Zasshi 1994;85: 151120.
  • 91
    Carani C, Granata AR, Bancroft J, Marrama P. The effects of testosterone replacement on nocturnal penile tumescence and rigidity and erectile response to visual erotic stimuli in hypogonadal men. Psychoneuroendocrinology 1995;20: 74353.
  • 92
    Montorsi F, Oettel M. Testosterone and sleep-related erections: An overview. J Sex Med 2005;2: 77184.
  • 93
    Shamloul R, Ghanem H, Fahmy I, El-Meleigy A, Ashoor S, Elnashaar A, Kamel I. Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: A pilot study. J Sex Med 2005;2: 55964.
  • 94
    Guay AT, Perez JB, Jacobson J, Newton RA. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl 2001;22: 7937.
  • 95
    Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vanelli GB, Aversa A, Natali A, Forti G, Giorgi M, Jannini EA, Ledda F, Maggi M. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004;146: 225363.
  • 96
    Cakir E, Ozcan O, Yaman H, Akgul EO, Bilgi C, Erbil MK, Yesilova Z. Elevated plasma concentration of asymmetric dimethylarginine that is reduced by single dose testosterone administration in idiopathic hypogonadotropic hypogonadism patients. J Clin Endocrinol Metab 2005;90: 16514.
  • 97
    Shabsigh R. Testosterone therapy in erectile dysfunction and hypogonadism. J Sex Med 2005;2: 78592.
  • 98
    Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychological correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151: 5461.
  • 99
    Deslypere JP, Vermeulen A. Leydig cell function in normal men: Effect of age, lifestyle, residence, diet, and activity. J Clin Endocrinol Metab 1984;59: 95562.
  • 100
    Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: Results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991;73: 101625.
  • 101
    Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 2001;86: 72431.
  • 102
    Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB. Age trends in the level of serum testosterone and other hormones in middle-aged men: Longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2002;87: 58998.
  • 103
    Wang C, Hikim AS, Ferrini M, Bonavera JJ, Vernet D, Leung A, Lue YH, Gonzalez-Cadavid NF, Swerdloff RS. Male reproductive ageing: Using the brown Norway rat as a model for man. Novartis Found Symp 2002;242: 8297.
  • 104
    Guay AT, Bansal S, Heatley GJ. Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: Double blind placebo-controlled trial with clomiphene citrate. J Clin Endocrinol Metab 1995;80: 354652.
  • 105
    Guay AT, Jacobson J, Perez JB, Hodge MB, Velasquez E. Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: Who does and does not benefit? Int J Impot Res 2003;15: 15665.
  • 106
    Guay AT. (Letter) RE: Long-term efficacy of sildenafil and tachylaxis effect. J Urol 2002;168: 2056.
  • 107
    Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: Results of the Cologne Male Survey. Int J Imp Res 2000;12: 30512.
  • 108
    Rosen RC, Fisher WA, Eardley I, Niederburger C, Nadel A, Sand M. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study. I: Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004;20: 60717.
  • 109
    Walczak MK, Lokhandwala N, Hodge MB, Guay AT. Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med 2002; 5: 1924.
  • 110
    Mancini A, Milardi S, Bianchi A, Summaria V, DeMarinis L. Increased estradiol levels in venous occlusive disorders: A possible functional mechanism of venous leakage. Int J Impot Res 2005;17: 23942.
  • 111
    Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW. Testosterone dose–response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001; 281: E117281.
  • 112
    Bhasin S, Taylor WE, Singh R, Artaza J, Sinha-Hikim I, Jasujao R, Choi H, Gonzalez-Cadavid NF. The mechanisms of androgen effects on body composition: Mesenchymal pluripotent cell as the target of androgen action. J Gerontol 2003;58A: 110310.
  • 113
    Rhoden EL, Ribeiro EP, Teloken C, Souto CA. Diabetes mellitus is associated with subnormal serum levels of free testosterone in men. BJU Int 2005;96: 86770.
  • 114
    Corona G, Mannucci E, Petrone L, Ricca V, Balercia G, Mansani R, Chiarini V, Giommi R, Forti G, Maggi M. Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. Int J Impot Res 2005;18: 1907.
  • 115
    Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiza GV. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003;6: 949.
  • 116
    Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf ) 2005;63: 23950.
  • 117
    Meusburger SM, Keast JR. Testosterone and nerve growth factor have distinct but interacting effects on structure and neurotransmitter expression of adult pelvic ganglion cells in vitro. Neuroscience 2001;108: 33140.
  • 118
    Keast JR, Gleeson RJ, Shulkes A, Morris MJ. Maturational and maintenance effects of testosterone on terminal axon density and neuropeptide expression in the rat vas deferens. Neuroscience 2002; 112: 3918.
  • 119
    Giuliano F, Rampin O, Schirar A, Jardin A, Rousseau JP. Autonomic control of penile erection: Modulation by testosterone in the rat. J Neuroendocrinol 1993;5: 67783.
  • 120
    Garban H, Vernet D, Freedman A, Rajfer J, Gonzalez-Cadavid N. Effect of aging on nitric oxide-mediated penile erection in rats. Am J Physiol 1995;268: H46775.
  • 121
    Garban H, Marquez D, Cai L, Rajfer J, Gonzalez-Cadavid NF. Restoration of normal adult penile erectile response in aged rats by long-term treatment with androgens. Biol Reprod 1995;53: 136572.
  • 122
    Penson DF, Ng C, Cai L, Rajfer J, Gonzalez-Cadavid NF. Androgen and pituitary control of penile nitric oxide synthase and erectile function in the rat. Biol Reprod 1996;55: 56774.
  • 123
    Shen Z, Chen Z, Lu Y, Chen F. Relationship between gene expression of nitric oxide synthase and androgens in rat corpus cavernosum. Chin Med J (Engl) 2000;113: 10925.
  • 124
    Marin R, Escrig A, Abreu P, Mas M. Androgen-dependent nitric oxide release in rat penis correlates with levels of constitutive nitric oxide synthase isoenzymes. Biol Reprod 1999;61: 10126.
  • 125
    Schirar A, Bonnefond C, Meusnier C, Devinoy E. Androgens modulate nitric oxide synthase messenger ribonucleic acid expression in neurons of the major pelvic ganglion in the rat. Endocrinology 1997;138: 3093102.
  • 126
    Seo SI, Kim SW, Paick JS. The effects of androgen on penile reflex, erectile response to electrical stimulation and penile NOS activity in the rat. Asian J Androl 1999;1: 16974.
  • 127
    Armagan A, Kim NN, Goldstein I, Traish AM. Dose–response relationship between testosterone and erectile function: Evidence for the existence of a critical threshold. J. Androl 2006 (in press).
  • 128
    Saenz de Tejada I, Moroukian P, Tessier J, Kim JJ, Goldstein I, Frohrib D. The trabecular smooth muscle modulates the capacitor function of the penis: Studies on a rabbit model. Am J Physiol 1991;250: H159095.
  • 129
    Saenz de Tejada I. Molecular mechanisms for the regulation of penile smooth muscle contractility. Int J Impot Res 2002;(1 suppl):S610.
  • 130
    Traish AM, Kim NN. The physiological role of androgens in penile erection: Regulation of corpus cavernosum structure and function. J Sex Med 2005;2: 75970.
  • 131
    Traish AM, Kim NN. Weapons of penile smooth muscle destruction: Androgen deficiency promotes accumulation of adipocytes in the corpus cavernosum. Aging Male 2005;8: 1416.
  • 132
    Persson C, Diederichs W, Lue TF, Yen TSB, Fishman IJ, McLin P, Tanagho EA. Correlation of altered penile ultrastructure with clinical arterial evaluation. J Urol 1989;142: 14628.
  • 133
    Mersdorf A, Goldsmith PC, Diederichs W, Padula CA, Lue TF, Fishman IJ, Tanagho EA. Ultrastructural changes in impotent penile tissue: A comparison of 65 patients. J Urol 1991;145: 74958.
  • 134
    Luangkhot R, Rutchik S, Agarwal V, Puglia K, Bhargava G, Melman A. Collagen alterations in the corpus cavernosum of men with sexual dysfunction. J Urol 1992;148: 46771.
  • 135
    Wespes E, Goes PM, Schiffmann S, Deprierreux M, Vanderhaeghen JJ, Schulman CC. Computerized analysis of smooth muscle fibers in potent and impotent patients. J Urol 1991;146: 10157.
  • 136
    Jevtich M, Khawand NY, Vidic B. Clinical significance of ultrastructural findings in the corpus cavernosa of normal and impotent men. J Urol 1990;143: 28993.
  • 137
    Wespes E, Schiffmann S, Depierreux M, Vanderhaegan JJ, Schulman CC. Is cavernovenous leakage related to a reduction of intracavernous smooth muscle fibers? Int J Impot Res 1990;2: 30 [abstract].
  • 138
    Moreland RB, Traish A, McMillin MA, Smith B, Goldstein I, Saenz de Tejada I. PGE1 suppresses the induction of collagen synthesis by transforming growth factor-beta 1 in human corpus cavernosum smooth muscle. J Urol 1995;153: 82634.
  • 139
    Raviv G, Vanegas JP, Petein M, Schulman C, Danguy A, Kiss R, Wespes E. Biochemical alterations of the tunica albuginea in impotence. J Urol 1997;158: 177882.
  • 140
    Raviv G, Kiss R, Vanegas JP, Petein M, Danguy A, Schulman C, Wespes E. Objective measurement of the different collagen types in the corpus cavernosum of potent and impotent men: An immunohistochemical staining with computerized-image analysis. World J Urol 1997;15: 505.
  • 141
    Udelson D, Nehra A, Hatzichristou DG, Azadzoi K, Moreland RB, Krane RJ, Saenz de Tejada IS, Goldstein I. Engineering analysis of penile hemodynamic and structural-dynamic relationships: Part I—Clinical implications of penile tissue mechanical properties. Int J Impot Res 1998;10: 1524.
  • 142
    Udelson D, Nehra A, Hatzichristou DG, Azadzoi K, Moreland RB, Krane RJ, Saenz de Tejada I, Goldstein I. Engineering analysis of penile hemodynamic and structural-dynamic relationships: Part II—Clinical implications of penile buckling. Int J Impot Res 1998;10: 2535.
  • 143
    Udelson D, Nehra A, Hatzichristou DG, Azadzoi K, Moreland RB, Krane RJ, Saenz de Tejada I, Goldstein I. Engineering analysis of penile hemodynamic and structural-dynamic relationships: Part III—Clinical considerations of penile hemodynamic and rigidity erectile responses. Int J Impot Res 1998;10: 8999.
  • 144
    Davila HH, Rajfer J, Gonzalez-Cadavid NF. Corporal veno-occlusive dysfunction in aging rats: Evaluation by cavernosometry and cavernosography. Urology 2004;64: 12616.
  • 145
    Shen ZJ, Zhou XL, Lu YL, Chen ZD. Effect of androgen deprivation on penile ultrastructure. Asian J Androl 2003;5: 336.
  • 146
    Moon DG, Sung DJ, Kim YS, Cheon J, Kim JJ. Bisphenol A inhibits penile erection via alteration of histology in the rabbit. Int J Impot Res 2001;13: 30916.
  • 147
    Moon DG, Lee KC, Kim YS, Park HS, Cho HY, Kim JJ. Effect of TCDD on corpus cavernosum histology and smooth muscle physiology. Int J Impot Res 2004;16: 22430.
  • 148
    Goyal HO, Braden TD, Williams CS, Dalvi P, Williams JW, Srivastava KK. Exposure of neonatal male rats to estrogen induces abnormal morphology of the penis and loss of fertility. Reprod Toxicol 2004;18: 26574.
  • 149
    Goyal HO, Braden TD, Williams CS, Dalvi P, Mansour MM, Mansour M, Williams JW, Bartol FF, Wiley AA, Birch L, Prins GS. Abnormal morphology of the penis in male rats exposed neonatally to diethylstilbestrol is associated with altered profile of estrogen receptor-alpha protein, but not of androgen receptor protein: A developmental and immunocytochemical study. Biol Reprod 2004;70: 150417.
  • 150
    Goyal HO, Braden TD, Williams CS, Dalvi P, Mansour MM, Williams JW. Permanent induction of morphological abnormalities in the penis and penile skeletal muscles in adult rats treated neonatally with diethylstilbestrol or estradiol valerate: A dose–response study. J Androl 2005;26: 3243.
  • 151
    Goyal HO, Braden TD, Williams CS, Dalvi P, Mansour M, Williams JW. Estrogen induced abnormal accumulation of fat cells in the rat penis and associated loss of fertility depends upon estrogen exposure during critical period of penile development. Toxicol Sci 2005;87: 24254.
  • 152
    Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 2003;144: 50818.
  • 153
    Corradi LS, Goes RM, Carvalho HF, Taboga SR. Inhibition of 5-alpha-reductase activity induces stromal remodeling and smooth muscle de-differentiation in adult gerbil ventral prostate. Differentiation 2004;72: 198208.
  • 154
    Rucker-Martin C, Pecker F, Godreau D, Hatem SN. Dedifferentiation of atrial myocytes during atrial fibrillation: Role of fibroblast proliferation in vitro. Cardiovasc Res 2002;55: 3852.
  • 155
    Johnson JL, Van Eys GJ, Angelini GD, George SJ. Injury induces dedifferentiation of smooth muscle cells and increased matrix-degrading metalloproteinase activity in human saphenous vein. Arterioscler Thromb Vasc Biol 2001;21: 114651.
  • 156
    Grillo ML, Jacobus AP, Scalco R, Amaral F, Rodrigues DO, Loss ES, Wassermann GF. Testosterone rapidly stimulates insulin release from isolated pancreatic islets through a non-genomic dependent mechanism. Horm Metab Res 2005;37: 6625.
  • 157
    Morimoto S, Mendoza-Rodriguez CA, Hiriart M, Larrieta ME, Vital P, Cerbon MA. Protective effect of testosterone on early apoptotic damage induced by streptozotocin in rat pancreas. J Endocrinol 2005;187: 21724.
  • 158
    Simopoulos DN, Gibbons SJ, Malysz J, Szurszewski JH, Farrugia G, Ritman EL, Moreland RB, Nehra A. Corporeal structural and vascular micro architecture with X-ray micro computerized tomography in normal and diabetic rabbits: Histopathological correlation. J Urol 2001;165: 177682.
  • 159
    Ahn GJ, Sohn YS, Kang KK, Ahn BO, Kwon JW, Kang SK, Lee BC, Hwang WS. The effect of PDE5 inhibition on the erectile function in streptozotocin-induced diabetic rats. Int J Impot Res 2005;17: 13441.
  • 160
    Morelli A, Filippi S, Luconi M, Vignozzi L, Zhang X-B, Luconi M, Domati S, Forti G, Maggi M. Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct models of chemical diabetes. J Sex Med 2006;45: abstract 156.
  • 161
    Sato Y, Suzuki N, Hisasue S-I, Kato R, Suzuki K, Tsukamoto T. Direct effects of testosterone on intracavernous pressure (ICP) elicited by electrical stimulation of the MPOA in male rats. Annual Meeting of the American Urological Association. 2005.

References

  • 1
    Ding D, Xu L, Menon M, Reddy GP, Barrack ER. Effect of a short CAG (glutamine) repeat on human androgen receptor function. Prostate 2004;58: 2332.
  • 2
    Alevizaki M, Cimponeriu AT, Garofallaki M, Sarika HL, Alevizaki CC, Papamichael C, Philippou G, Anastasiou EA, Lekakis JP, Mavrikakis M. The androgen receptor gene CAG polymorphism is associated with the severity of coronary artery disease in men. Clin Endocrinol 2003;59: 74955.
  • 3
    Krishnaswamy V, Kumarasamy T, Venkatesan V, Shroff S, Jayanth VR, Paul SF. South Indian men with reduced CAG repeat length in the androgen receptor gene have an increased risk of prostate cancer. J Hum Genet 2006 (in press).
  • 4
    Labrie F, Luu-The V, Labrie C, Belanger A, Simard J, Lin SX, Pelletier G. Endocrine and intracrine sources of androgens in women: Inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003;24: 15282.

References

  • 1
    Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW. Testosterone dose—response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001;281: E117281.
  • 2
    Buena F, Swerdloff RS, Steiner BS, Lutchmansingh P, Peterson MA, Pandian MR, Galmarini M, Bhasin S. Sexual function does not change when serum testosterone levels are pharmacologically varied within the normal male range. Fertil Steril 1993;59: 111823.
  • 3
    Gooren LJ. Androgen levels and sex functions in testosterone-treated hypogonadal men. Arch Sex Behav 1987;16: 46373.
  • 4
    Schiavi RC, Rehman J. Sexuality and aging. Urol Clin North Am 1995;22: 71126.
  • 5
    Gray PB, Singh AB, Woodhouse LJ, Storer TW, Casaburi R, Dzekov J, Dzekov C, Sinha-Hikim I, Bhasin S. Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J Clin Endocrinol Metab 2005;90: 383846.
  • 6
    Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003;88: 267381.
  • 7
    Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: Results of a meta-analysis. J Urol 2000;164: 3715.
  • 8
    Zitzmann M, Nieschlag E. The CAG repeat polymorphism within the androgen receptor gene and maleness. Int J Androl 2003;26: 7683.
  • 9
    Harkonen K, Huhtaniemi I, Makinen J, Hubler D, Irjala K, Koskenvuo M, Oettel M, Raitakari O, Saad F, Pollanen P. The polymorphic androgen receptor gene CAG repeat, pituitary-testicular function and andropausal symptoms in ageing men. Int J Androl 2003;26: 18794.
  • 10
    Raivio T, Palvimo JJ, Dunkel L, Wickman S, Janne OA. Novel assay for determination of androgen bioactivity in human serum. J Clin Endocrinol Metab 2001;86: 153944.